Table 1.
Patient's clinical and laboratory characteristics.
| Clinical and laboratory characteristics | Rapa group | CsA group | P |
|---|---|---|---|
| Patients number | 43 | 45 | |
| Females/males | 29/14 | 32/13 | 0.713 |
| Mean age, years | 34 (13–65) | 36 (14–58) | 0.456 |
| Mean duration, years | 3 (2–6) | 3 (2–6) | 0.420 |
| Mean bleeding grade (WHO Bleeding Scale) | 1 (0–2) | 1 (0–2) | 0.377 |
| Mean baseline platelet count, ×109/L | 22.25 (11–32) | 21.82 (11–35) | 0.747 |
| Mean MEG count in bone marrow slide | 105 (34–231) | 100 (34–241) | 0.710 |
| Platetle antibody, yes/no | 28/15 | 28/17 | 0.781 |
| Mean days since the last treatment | 63 (10–365) | 57 (10–365) | 0.664 |
| Mean numbers of previous treatments | 3 (2–6) | 3 (2–5) | 0.106 |
| Previous treatments number | 43 | 45 | |
| Steroids | 43 | 45 | |
| Intravenous immune globulin | 17 | 21 | |
| Danazol | 16 | 19 | |
| Azathioprine | 10 | 14 | |
| Vincristine | 2 | 1 | |
| Rituximab | 1 | 0 |
The previous treatments included Steroids, intravenous immune globulin, Rituximab, Danazol, Azathioprine, and Vincristine; the determination of platelet antibody included glycoproteins IIb/IIIa/Ib/IX.
MEG: megakaryocyte; Rapa: rapamycin; CsA: cyclosporine A.